Form 4: MaxCyte Director John Johnston Executes Stock Option and Sells Shares Under 10b5-1 Plan

Director John Johnston exercised stock options and sold shares of MaxCyte, Inc. under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On January 27, 2025, John Johnston, a director of MaxCyte, Inc., exercised stock options to acquire 3,000 shares of common stock at a price of $2.932 per share.
• Simultaneously, Johnston sold 3,000 shares of MaxCyte common stock at a weighted average price of $4.645 per share, with individual sales prices ranging from $4.52 to $4.72.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on December 19, 2023.
• Following these transactions, Johnston directly owns 141,950 shares of MaxCyte common stock and 17,417 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports routine transactions under a pre-arranged trading plan. There is no indication of positive or negative implications for the company.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

• Director selling activity could be perceived negatively by investors, although the 10b5-1 plan mitigates this concern.

Industry Context

Form 4 filings are standard disclosures for corporate insiders and provide transparency into their trading activities. The use of a 10b5-1 plan is a common practice to allow insiders to sell shares without raising concerns about trading on non-public information.

Comparison to Industry Standards

• Corporate insiders regularly use 10b5-1 trading plans to manage their stock holdings, similar to practices seen at companies like Amgen (AMGN) and Regeneron (REGN).
• The reported transactions are typical for directors and officers managing their personal finances and stock-based compensation.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the director's sale of shares, but the 10b5-1 plan mitigates concerns about insider trading.

Key Dates